Hansoh Pharmaceutical Group Company Limited (HNSPF)

Market Cap	28.02B -2.9%
Revenue (ttm)	2.34B +20.5%
Net Income	983.17M +39.7%
EPS	0.16 +37.9%
Shares Out	n/a
PE Ratio	28.50
Forward PE	28.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	4.540
Previous Close	4.548
Day's Range	4.540 - 4.610
52-Week Range	3.825 - 5.160
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About HNSPF

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 9,643
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNSPF

Financial Performance

In 2025, HNSPF's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 4, 2026

Data Sources Report a data error